{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:03:59Z","timestamp":1777277039846,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00259-025-07744-8","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T01:31:59Z","timestamp":1768354319000},"page":"3581-3589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of [225Ac]Ac\/[177Lu]Lu-PSMA-therapy"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7026-9203","authenticated-orcid":false,"given":"Gabriel T.","family":"Sheikh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie C.","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liam","family":"Widjaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah L.","family":"Takayama Fouladgar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Delker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jozefina","family":"Casuscelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena M.","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf. A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias J.","family":"Zacherl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"7744_CR1","unstructured":"Institute NC. Cancer stat facts: prostate cancer. 2023 [cited 2023 04.08.2023]; Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html"},{"issue":"12","key":"7744_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"key":"7744_CR3","doi-asserted-by":"crossref","unstructured":"Sathekge MM, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. The Lancet Oncology. 2024.","DOI":"10.1016\/S1470-2045(23)00638-1"},{"issue":"3","key":"7744_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","volume":"79","author":"B Feuerecker","year":"2021","unstructured":"Feuerecker B, et al. Activity and adverse events of Actinium-225-PSMA-617 in advanced metastatic Castration-resistant prostate cancer after failure of Lutetium-177-PSMA. Eur Urol. 2021;79(3):343\u201350.","journal-title":"Eur Urol"},{"key":"7744_CR5","doi-asserted-by":"crossref","unstructured":"Kratochwil C, Haberkorn U, Giesel FL. 225Ac-PSMA-617 for therapy of prostate cancer. In Seminars in nuclear medicine 2020 Mar 1;50(2):133\u2013140. WB Saunders.","DOI":"10.1053\/j.semnuclmed.2020.02.004"},{"issue":"5","key":"7744_CR6","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00259-022-06092-1","volume":"50","author":"A Delker","year":"2023","unstructured":"Delker A, et al. Biodistribution and dosimetry for combined [177Lu] Lu-PSMA-I&T\/[225Ac] Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging. Eur J Nucl Med Mol Imaging. 2023;50(5):1280\u201390.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"7744_CR7","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.2967\/jnumed.123.265433","volume":"64","author":"C Meyer","year":"2023","unstructured":"Meyer C, et al. Tandem isotope therapy with 225Ac-and 177Lu-PSMA-617 in a murine model of prostate cancer. J Nucl Med. 2023;64(11):1772\u20138.","journal-title":"J Nucl Med"},{"issue":"1","key":"7744_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13550-025-01211-z","volume":"15","author":"GT Sheikh","year":"2025","unstructured":"Sheikh GT, et al. RECIP 1.0\u2009+\u2009PSA for response assessment in mCRPC patients treated with 225Ac\/177Lu PSMA combination therapy. EJNMMI Res. 2025;15(1):19.","journal-title":"EJNMMI Res"},{"issue":"5","key":"7744_CR9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2967\/jnumed.120.251017","volume":"62","author":"MJ Zacherl","year":"2021","unstructured":"Zacherl MJ, et al. First clinical results for PSMA-targeted \u03b1-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients. J Nucl Med. 2021;62(5):669\u201374.","journal-title":"J Nucl Med"},{"issue":"1","key":"7744_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-014-0063-1","volume":"4","author":"M Weineisen","year":"2014","unstructured":"Weineisen M, et al. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res. 2014;4(1):1\u201315.","journal-title":"EJNMMI Res"},{"key":"7744_CR11","doi-asserted-by":"crossref","unstructured":"Mittlmeier LM, et al. Feasibility of different tumor delineation approaches for 18F-PSMA-1007 PET\/CT imaging in prostate cancer patients. Frontiers in oncology, 2021;11:663631.","DOI":"10.3389\/fonc.2021.663631"},{"issue":"11","key":"7744_CR12","first-page":"1651","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, et al. Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic Castration-Resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022;63(11):1651\u20138.","journal-title":"J Nucl Med"},{"issue":"12","key":"7744_CR13","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402.","journal-title":"J Clin Oncol"},{"key":"7744_CR14","unstructured":"Institute NC. Common terminology criteria for adverse events (CTCAE) version 5.0. U.S. Department of Health and Human Services, National Cancer Institute; 2017."},{"issue":"10","key":"7744_CR15","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","volume":"58","author":"C Kratochwil","year":"2017","unstructured":"Kratochwil C, et al. Targeted alpha-Therapy of metastatic Castration-Resistant prostate cancer with (225)Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58(10):1624\u201331.","journal-title":"J Nucl Med"},{"issue":"20","key":"7744_CR16","doi-asserted-by":"publisher","first-page":"9364","DOI":"10.7150\/thno.48107","volume":"10","author":"MP Yadav","year":"2020","unstructured":"Yadav MP, et al. Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients. Theranostics. 2020;10(20):9364.","journal-title":"Theranostics"},{"issue":"3","key":"7744_CR17","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","volume":"47","author":"F Khreish","year":"2020","unstructured":"Khreish F, et al. 225Ac-PSMA-617\/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47(3):721\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"7744_CR18","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.3390\/pharmaceutics14102166","volume":"14","author":"SW Ling","year":"2022","unstructured":"Ling SW, et al. Advances in 177Lu-PSMA and 225Ac-PSMA radionuclide therapy for metastatic castration-resistant prostate cancer. Pharmaceutics. 2022;14(10):2166.","journal-title":"Pharmaceutics"},{"issue":"9","key":"7744_CR19","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.7150\/thno.56211","volume":"11","author":"F Rosar","year":"2021","unstructured":"Rosar F, et al. Molecular imaging and biochemical response assessment after a single cycle of [225Ac] Ac-PSMA-617\/[177Lu] Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu] Lu-PSMA-617 monotherapy. Theranostics. 2021;11(9):4050.","journal-title":"Theranostics"},{"key":"7744_CR20","doi-asserted-by":"crossref","unstructured":"Kulkarni H et al. Radioligand therapy using combination of Ac-225 and Lu-177 labelled PSMA ligands for progressive end-stage metastatic prostate cancer: effective trade-off between response and toxicity. Soc Nuclear Med. 2019.","DOI":"10.1055\/s-0039-1683560"},{"issue":"8","key":"7744_CR21","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.7150\/thno.106574","volume":"15","author":"G Ninatti","year":"2025","unstructured":"Ninatti G, et al. Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer-a systematic review and meta-analysis. Theranostics. 2025;15(8):3386.","journal-title":"Theranostics"},{"key":"7744_CR22","doi-asserted-by":"crossref","unstructured":"Langbein T et al. Salivary gland toxicity of PSMA-targeted radioligand therapy with 177Lu-PSMA and combined 225Ac-and 177Lu-labeled PSMA ligands (TANDEM-PRLT) in advanced prostate cancer: a single-center systematic investigation. Diagnostics. 2022; 12(8):1926.","DOI":"10.3390\/diagnostics12081926"},{"key":"7744_CR23","unstructured":"Novruzov F et al. Tandem therapy versus single agent 177Lu-PSMA and 225Ac-PSMA therapy of advanced stage metastatic castration resistant prostate carcinoma: clinical trial from Azerbaijan. Soc Nuclear Med. 2022."},{"issue":"10","key":"7744_CR24","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","volume":"58","author":"C Kratochwil","year":"2017","unstructured":"Kratochwil C, et al. Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58(10):1624\u201331.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07744-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07744-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07744-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:26:31Z","timestamp":1777274791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07744-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7744"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07744-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Ludwig-Maximilians-University Munich (Date 21.03.2025\/No 25-0130).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was waived by the Ethics Committee of the Ludwig-Maximilians-University Munich due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Rudolf A. Werner has served on the advisory board work for Novartis\/AAA and Bayer and has received speaker honoraria from Novartis\/AAA and PentixaPharm. Lena M. Unterrainer has received speaker honoraria from Novartis and Astellas Pharma Inc. and has served as a consultant for Telix. The other authors (Gabriel T. Sheikh, Sophie C. Siegmund, Liam Widjaja, Sarah L. Takayama Fouladgar, Astrid Delker, Jozefina Casuscelli, Mathias J. Zacherl) have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}